Navigation Links
Hemaclear Announces First Annual Italian Distributor and User Conference: May 22, 2013 in Rome, Italy

Haifa, Israel (PRWEB) May 15, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it will hold its first annual Italian distributor and user conference; May 22, 2013 in Rome, Italy. The conference will be the first time Hemaclear users and distributors from Italy will meet to discuss the competitive and clinical advantage of the novel tourniquet.

Since the launch of Hemaclear in 2008 in Italy, the novel tourniquet has quickly become the standard of care at many Italian hospitals and clinics. Over the past 5 years regional distributors have recognized the positive business contributions of the device, while surgeons have recognized the positive clinical contributions. In a country where reusable pneumatic tourniquets were the standard of care prior to the launch of Hemaclear, physicians and patients can now experience the benefits of a reliable, safe, and sterile tourniquet.

“We are very excited to have the opportunity to meet with our distributor partners and surgeon users in Rome. This conference will provide all an opportunity to learn, network, and further discuss our commercialization efforts in Italy,” said Omer Inbar, CEO, OHK Medical Devices. Mr. Inbar added, “After a very strong year in 2012, we hope to continue the positive momentum in Italy. We strive to increase our Italian distribution network, and surgeon user base.”

OHK Medical Devices will be hosting the meeting May 22, 2013 at the Sofitel Rome Villa Borghese. To schedule a meeting or learn more about the conference please email info(at)hemaclear(dot)com.

About HemaClear®

HemaClear® is the world’s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. HemaClear Launches Activity in APAC
2. IntraMed Diagnostics Announces Two Senior-Level Additions
3. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
4. Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
5. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
6. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
7. Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
8. Yongye International Announces First Quarter 2013 Financial Results
9. Vestiage Announces Initial Advisory Board Members
10. PDL BioPharma Announces First Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):